AAAAAA

   
Results: 1-11 |
Results: 11
Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine
Authors: Moyle, GJ Gazzard, BG
Citation: Gj. Moyle et Bg. Gazzard, Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine, AIDS, 15(6), 2001, pp. 799-800
Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy
Authors: Moyle, GJ Lloyd, M Reynolds, B Baldwin, C Mandalia, S Gazzard, BG
Citation: Gj. Moyle et al., Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy, AIDS, 15(12), 2001, pp. 1503-1508
Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initialtherapy
Authors: Matthews, GV Moyle, GJ Mandalia, S Bower, M Nelson, M Gazzard, BG
Citation: Gv. Matthews et al., Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initialtherapy, J ACQ IMM D, 24(4), 2000, pp. 310-315
Fresh starting points for HIV's second century
Authors: Moyle, GJ
Citation: Gj. Moyle, Fresh starting points for HIV's second century, CURR OPIN I, 13(1), 2000, pp. 1-3
Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection
Authors: Moyle, GJ
Citation: Gj. Moyle, Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection, CURR OPIN I, 13(1), 2000, pp. 19-25
Frequency of multinucleoside analogue-resistant genotypes observed during antiretroviral therapy
Authors: Moyle, GJ Basar, A Gazzard, BG
Citation: Gj. Moyle et al., Frequency of multinucleoside analogue-resistant genotypes observed during antiretroviral therapy, AIDS, 14(9), 2000, pp. 1292-1293
Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use
Authors: Moyle, GJ Wilkins, E Leen, C Cheesbrough, A Reynolds, B Gazzard, BG
Citation: Gj. Moyle et al., Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use, AIDS, 14(10), 2000, pp. 1453-1454
Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy
Authors: Moyle, GJ Baldwin, C
Citation: Gj. Moyle et C. Baldwin, Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy, J ACQ IMM D, 21(5), 1999, pp. 423-424
Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy
Authors: Moyle, GJ Sadler, M Buss, N
Citation: Gj. Moyle et al., Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy, CLIN INF D, 28(2), 1999, pp. 403-404
A risk-benefit assessment of HIV protease inhibitors
Authors: Moyle, GJ Gazzard, BG
Citation: Gj. Moyle et Bg. Gazzard, A risk-benefit assessment of HIV protease inhibitors, DRUG SAFETY, 20(4), 1999, pp. 299-321
Peripheral neuropathy with nucleoside antiretrovirals - Risk factors, incidence and management
Authors: Moyle, GJ Sadler, M
Citation: Gj. Moyle et M. Sadler, Peripheral neuropathy with nucleoside antiretrovirals - Risk factors, incidence and management, DRUG SAFETY, 19(6), 1998, pp. 481-494
Risultati: 1-11 |